Radical prostatectomy (RP) is a standard surgical treatment of clinically localized prostate cancer (PCa.
Patients who undergo RP experience 15-yr cancer-specific mortality (CSM) ranging from 7% to 20%. Conversely, 15-yr biochemical recurrence (BCR)–free survival estimates may be as high as 75%. These figures were obtained in series of retropubic RPs (RRPs) performed in US and European referral centers. Robot-assisted RP (RARP) also has become very popular in the United States and Europe; it has been estimated that >75% of RPs are performed using the da Vinci platform (Intuitive Surgical, Inc., Sunnyvale, CA, USA)